504833765 03/23/2018

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4880502

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date	
HELIX BIOPHARMA CORP.	01/31/2017	

RECEIVING PARTY DATA

Name:	XISLE PHARMA VENTURES TRUST
Street Address:	GENEVA PLACE,
Internal Address:	333 WATERFRONT DRIVE
City:	ROAD TOWN, TORTOLA
State/Country:	VIRGIN ISLANDS, BRITISH
Postal Code:	VG1110

PROPERTY NUMBERS Total: 3

Property Type	Number
Patent Number:	6165458
Patent Number:	6444200
Patent Number:	6656499

CORRESPONDENCE DATA

Fax Number: (416)865-1515

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 416-865-4708

Email: lbartoszewicz@airdmcburney.com

Correspondent Name: LOLA BARTOSZEWICZ

Address Line 1: AIRD & MCBURNEY LP, BROOKFIELD PLACE

Address Line 2: 181 BAY STREET, SUITE 1800
Address Line 4: TORONTO, CANADA M5J 2T9

ATTORNEY DOCKET NUMBER:	16082-1 LAB
NAME OF SUBMITTER:	LOLA A. BARTOSZEWICZ
SIGNATURE:	/Lola A. Bartoszewicz/
DATE SIGNED:	03/23/2018

Total Attachments: 5

source=Assign Helix to Xisle#page1.tif source=Assign Helix to Xisle#page2.tif

PATENT 504833765 REEL: 045323 FRAME: 0946

source=Assign Helix to Xisle#page3.tif
source=Assign Helix to Xisle#page4.tif
source=Assign Helix to Xisle#page5.tif

CONFIRMATORY ASSIGNMENT

WHEREAS, HELIX BIOPHARMA CORP., (hereinafter referred to as "ASSIGNOR"), having a place of business at 21 St. Clair Avenue East, Suite 1100, Toronto, Ontario, M4T 1L9, Canada, is the owner of the Letters Patent and patent applications set out in Schedule A attached hereto; and

WHEREAS, XISLE PHARMA VENTURES TRUST, (hereinafter referred to as "ASSIGNEE"), having a place of business at Geneva Place, 333 Waterfront Drive, Road Town, Tortola, British Virgin Islands, is desirous of acquiring the exclusive right, title and interest in and to the said Letters Patent and patent applications.

NOW THEREFORE to all whom it may concern be it known that for and in consideration of the sum of one dollar (\$1.00) to them in hand paid by the said Assignee and other good and valuable consideration the receipt of which is hereby acknowledged, the said Assigner hereby confirms that they have as of November 18, 2016, assigned and transferred to the said Assignee, its successors and assigns, their entire right, title and interest in and to the said inventions for all countries and in and to the said U.S. Patent Applications and all Letters Patent that may be obtained therefor in the U.S., and in and to any corresponding patents and patent applications therefor in other countries.

AND the said Assignor hereby authorizes and requests the Patent Office to issue Letters Patent for the said inventions to said Assignce, the assignee of the entire right, title and interest in and to the same, for its sole use and benefit; and for the use and benefit of its successors and assigns, to the full end of the term for which a U.S. Letters Patent may be granted, as fully and entirely as the same would have been held by them had this assignment and sale not been made.

We hereby undertake without liability at any time upon request to do everything legally possible to assist the said Assignee in the filing and prosecution of any patent application relating to the said inventions in any country, to sign such documents and do such things as may be required to give effective legal and registered title of the said Assignee to the inventions in any country, all without further consideration but at the expanse of the said Assignee.

٨	SIGNED at Townto, on this 31 day of Jan	2017
/h ·	Jemist.	
Assignor	Assigner Helix BioPharma Corp.	•
J	Name: Heman Chao	
	Title: CSO	

STATEMENT OF WITNESS

, Steve	: Demas
hereby declare that I w	as personally present and did see HEMAL (HAO, who is personally erson in the attached assignment, duly sign and execute the same.
SIGNED at TOPON (ON this 31 day of JAN , 2017.
Signature of Witness	Seun

Assigne	SIGNED at Totals, B. V. I this 31 day of JANUARY, 2017. Checkenson, Riste Pharma Ventures Trust Name: MENDE WALLOW Trust Title: Co-TRUSTEE
	STATEMENT OF WITNESS THOMAS
	hereby declare that I was personally present and did see MFANEMALORE who is personall known to me to be the person in the attached assignment, duly sign and execute the same.
	SIGNED at Torfold, B. V.I., this 31st day of JANUARY, 2017.
1	Signature of Witness

SCHEDULE A

Title:

Biphasic Lipid-Vesicle Compositions And Methods For Treating Cervical

Dysplasia By Intravaginal Delivery

Inventor(s):

Praveen Kumar

Our Reference	Country	Filing Date	Filing Number	Based On	Issue Date	Issue Number
16082-2 (134066) LAB	U.S.	August 12, 2013	13/965,122	Original Application	March 24, 2015	8,986,732
16082-3 LAB	PCT	August 11, 2014	PCT/US2014/050590 (WO 2015/023600)	US 13/965,122	n/a	n/a
16082-4 (134068) LAB	U.S.	August 12, 2013	14/059,369	Divisional of US 13/965,122	March 31, 2015	8,992,969
16082-5 (134067) LAB	U.S.	August 12, 2013	14/059,373	Divisional of US 13/965,122	April 21, 2015	9,011,924

Title:

Biphasic Lipid-Vesicle Compositions And Methods For Treating Cervical

Dysplasia By Intravaginal Delivery

Inventor(s):

Praveen Kumar

Our Reference	Country	Filing Date	Filing Number	Based On	Issue Date	Issue Number	Expiry Date
16082-6 (134069) LAB	U.S.	August 12, 2013	13/965,158	Original Application			
16082-7 LAB	РСТ	August 11, 2014	PCT/US2014/050591 (WO 2015/023601)	US 13/965,158	n/a	n/a	n/a

^{*}U.S. 6,165,458 === 16082-8

^{*}U.S. 6,444,200 =-- 16082-9

^{*}U.S. 6,656,499 ==== 16082-10

^{*} all annuities paid

Biphasic Lipid-Vesicle Composition And Method For Treating Cervical Dysplasia By Intravaginal Delivery Marianna Foldvarl, Praveen Kumar, John Docherty Title:

Inventor(s):

Our Reference	Country	Filing Date	Filing Number	Based On	Issue Date	Issue Number
16082-11 LAB	U. S .	March 30, 2007	60/909-324 vi-ii	Original Application:		
16082-12 LAB	PC	March 27, 2 2008	PCT/CA2008/00563 (WG-2008/119160)	US 60/909324		
16082-13 (134073) LAB	Australia		2008234364		January 30, 2014	20082343 64
16082-14 (134072)	Taiwan		9711592			1440477
16082-15 (133321) LAB	Canada		2,681,565			
160082-16 (134074) LAB	Europe		2008733666 (08733666.5)			
16082-17 (134076) LAB	Hong Kong	March 27, 2008	10102315.2	PCT/CA2008/000563 (WO 2008/119160)		along the second
16082-18 (134077)	Јарап		2010-500036			
16082-19c (134078) LAB	Korea		10420017022180			
16082-20 (134079)	Mexico		MX/a/2009/010405			
16082-21 (134080) LAB	U.S.		12/532752		February 3, 2015	8,945,529
16082-22 LAB	Uis:	March 27, 2008	12/84945 28 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Djýlsjoha) of US 12532-752j E		
)6082-23 LAB	Ü.S	March 2777 2 2777 2 2008 2		Gontinuation of US, 17		

PATENT REEL: 045323 FRAME: 0952

RECORDED: 03/23/2018